Phase 3 Irritable Bowel Syndrome Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing to give written consent to take part before any screening begins
- You have been diagnosed with Irritable Bowel Syndrome (IBS) that does not involve mainly constipation, based on standard medical criteria called Rome IV
- Tests have ruled out other conditions that could explain your symptoms, such as coeliac disease (blood test), lactose intolerance (breath test), inflammatory bowel disease, and a gut infection called giardiasis (stool test)
- If you have lactose intolerance, you may still be able to join if avoiding lactose for 6 weeks did not improve your symptoms
- You are between 18 and 65 years old
Who may not be able to join:
- You have a history of coeliac disease, food allergy, giardiasis, inflammatory bowel disease, stomach or gut infection, a gut movement disorder, serious liver, kidney, heart or lung disease, known heart rhythm problems, insulin-dependent diabetes, or a psychiatric illness
- You are currently pregnant or breastfeeding
- You are taking certain medications, including antidepressants, antipsychotics, antihistamines/allergy medicines, medicines that affect gut movement or sensitivity, most painkillers (only paracetamol is allowed), or certain other drugs that interact with how the body processes medicines — including some antibiotics, antifungals, heart medicines, and herbal products like St. John's Wort or grapefruit (confirm with trial site for the full list)
- Your IBS symptoms began after abdominal surgery
- Your IBS is mainly constipation-type (known as IBS-C)
- You have a known allergy or sensitivity to the active ingredient or any component of the trial medication (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Guy Boeckxstaens, prof. dr., KU Leuven
Phone: +3216341943
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinical Response to Abdominal Pain Intensity; Clinical Response to Global Relief of Symptoms
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.